As­traZeneca punts NASH drug from an ail­ing Reg­u­lus as their lead pro­gram goes un­der for the last time

The drum­beat of bad news at Reg­u­lus is con­tin­u­ing with a rapid tem­po to­day.

Not sur­pris­ing­ly, Reg­u­lus has opt­ed to kill off its lead RNAi pro­gram for HCV af­ter it lin­gered for months un­der a full FDA hold on safe­ty is­sues. But its painful up­date to­day al­so dis­clos­es that As­traZeneca has punt­ed back rights to a NASH drug — AZD4076 (RG-125) — two years af­ter the phar­ma gi­ant stepped in with a deal for it. And an­oth­er pro­gram for RGLS5040 has been dis­con­tin­ued as well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER